Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
flu vaccine
Biotech
Osivax focuses on combo strategy for flu shot after ph. 2 fail
Osivax has been forced to narrow the strategy for its influenza vaccine after the shot failed a phase 2b study.
James Waldron
Oct 15, 2026 8:07am
Osivax bags flu vaccine rights to pursue combination shot vision
Aug 27, 2026 10:00am
Fierce Pharma
Novavax bets on ‘amplification strategy’ with Sanofi, Pfizer deals
Apr 6, 2026 8:37am
FDA accepts filing for Moderna flu vaccine after swift rethink
Feb 18, 2026 9:21am
HHS stands behind FDA decision to spurn Moderna flu filing
Feb 11, 2026 3:13pm
Moderna hit with FDA refusal-to-file letter for mRNA flu shot
Feb 10, 2026 7:45pm
